)
)
Affimed Investor Relations Material
Latest events
Study Update
Affimed
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Affimed N.V.
Access all reports
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. The company operates through two segments, Affimed Therapeutics, and Redoxa GmbH. It develops therapies based on its proprietary TandAb platform to unleash the innate power of the immune system by harnessing the functionality of natural killer cells and T-cells for the treatment of cancer.
The company has strategic partnerships with Genentech Inc.; Merck KGaA and Pfizer Inc.; Novartis Institutes for BioMedical Research, Inc.; Celgene Corporation; Bayer Pharma AG; MorphoSys AG; Incyte Corporation; Amgen Inc.; Hoffmann-La Roche ltd; Sanofi S.A.; and Bristol-Myers Squibb Company. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany
Key slides for Affimed N.V.
Study Update
Affimed N.V.
Study Update
Affimed N.V.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
AFMD
Country
🇺🇸 United States